A Study on Oral Tofacitinib for Prurigo Nodularis: Clinical Outcomes and Skin Imaging Analysis

Clinical and Dermoscopic Profile of Prurigo Nodularis on Oral Tofacitinib Therapy - An Interventional Study. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/108196

Enrollment

Registered

2026-04-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L281- Prurigo nodularis

Interventions

Intervention1: oral tofacitinib: Tablet Tofacitinib 5mg orally,twice a day for 3 months or Tablet Tofacitinib 11mg orally , once a day for 3 months Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with biopsy proven prurigo nodularis, not responding to conventional treatments. Age above 18 yrs. Subjects willing to give consent to participate in the study.

Exclusion criteria

Exclusion criteria: Pregnancy or Lactation. Subjects using of systemic glucocorticoids or immune suppressive agents in the last 4 weeks. Abnormal findings in Complete Blood Picture , Liver Function Test , Renal Function Test , Fasting Lipid Profile . Any infections, inflammation, or active tumors

Design outcomes

Primary

Measure	Time frame
To evaluate clinical and dermoscopic features of prurigo nodularis before and after treatment with oral tofacitinib therapyTimepoint: Baseline and 18 months	—

Secondary

Measure	Time frame
providing data on the efficacy and safety profile of oral tofacitinib in patients diagnosed with prurigo nodularis.Timepoint: 18 months	—

Countries

India

Contacts

Public ContactKANTAMANI SWATHI

GSL MEDICAL COLLEGE AND GENERAL HOSPITAL

seetharamka@gmail.com9440250197

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026